[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tricuspid-insufficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tricuspid-insufficiency":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":4},"100638696","pascal-precision-gdmt-registry-100638696",false,"NCT07578129","PASCAL Precision-GDMT Registry","Improvement in Guideline-Directed Medical Therapy After Tricuspid Transcatheter Edge-to-Edge Repair in Participants With Reduced Left Ventricular Function","PASCAL","Inclusion Criteria:\n\n* Participants of age ≥ 18 years\n* ≥ severe tricuspid regurgitation\n* LVEF \\\u003C 50%\n* Written informed consent of the patient or her\u002Fhis legal representative\n* Patient understands the purpose, the potential risks as well as benefits of the trial and is willing to participate in all parts of the follow-up\n* Planned follow-up within a dedicated heart failure clinic as part of routine care.\n\nExclusion Criteria:\n\n* Anatomy unsuitable for TEER as determined by local heart team\n* severe mitral regurgitation (defined as an EROA\\>40 mm2) treated (surgically or percutaneously) less than 3 months prior\n* severe left ventricular dysfunction (defined as an LVEF \\\u003C20%)\n* systolic pulmonary artery pressure \\>70 mmHg (right heart catheterization)\n* prior tricuspid valve intervention\n* severe leaflet degeneration or tricuspid valve anatomy precluding successful device placement\n* primary tricuspid valve disease\n* COPD requiring home oxygen therapy\n* active endocarditis, or recent episode within 4 weeks of discontinuation of antibiotic therapy\n* participants with unstable hemodynamic condition\n* significant co-morbidities resulting in an expected less than 12-month life expectancy\n* The presence of other anatomic or comorbid conditions or other medical, social or psychological conditions that in the investigators' opinion could limit the subject's ability to participate in the clinical study and its follow-up.\n* Participants under judicial protection, guardianship or curatorship or if they are deprived of their liberty by judicial or administrative decision\n* Participation in another trial, which would lead to deviations in the preparation or performance of the intervention or the post-implantation management from this protocol","ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","12 Months","OBSERVATIONAL","The goal of this observational study is to demonstrate that successful tricuspid valve repair with the PASCAL Precision System in participants with at least severe tricuspid insufficiency and left ventricular dysfunction will be associated with an improvement in up-titration of guideline-directed medical therapy (GDMT). The main question it aims to answer is:\n\nDoes the tricuspid insufficiency repair with the Pascal Precision System increases the dose of the medications used for heart failure therapy in the study population 12 months after tricuspid repair, as compared to the dose taken at baseline.\n\nParticipants undergoing tricuspid repair and fulfilling all inclusion\u002Fexclusion criteria will be asked to answer heart failure assessment as well as quality of life questionnaires at baseline and at 12 months post intervention. Medication monitoring will be performed throughout the study.",[26,27,28,29,30,31],"Tricuspid Insufficiency","Tricuspid Regurgitation (TR)","Left Ventricular Cardiac Dysfunction","Left Ventricular (LV) Systolic Dysfunction","Left Ventricular Dysfunction","Left Ventricular Ejection Fraction",[33,34,35,36,37,38],"T-TEER","Severe Tricuspid regurgitation","left ventricular dysfunction","GDMT score","NHYA","KCCQ","NOT_YET_RECRUITING","2026-05-11",{"date":42,"type":43},"2026-05-13","ACTUAL",{"date":45,"type":21},"2026-08-01",{"date":47,"type":21},"2027-08-31",{"name":49,"class":50},"Ceric Sàrl","INDUSTRY",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":72,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":90},"100545096","influence-of-lung-ultrasonography-on-the-prognosis-and-postoperative-outcomes-in-cardiac-surgical-patients-100545096","NCT06377449","Influence of Lung Ultrasonography on the Prognosis and Postoperative Outcomes in Cardiac Surgical Patients","Influence of Ultrasound Examination of the Lungs on the Prognosis and Postoperative Outcomes in Cardiac Surgical Patients","Inclusion Criteria:\n\n* open heart surgery with cardiopulmonary bypass (CPB) between 15 December 2023 and 15 December 2024\n* signed informed consent for participation in the study\n\nExclusion Criteria:\n\n* reoperations on the open heart with CPB\n* surgical procedures on lungs and lung cancer in the anamnesis\n* chronic obstructive pulmonary disease, stage III\n* chronic kidney disease, stages 4 and 5\n* patients with low Risk Score profile by the Society of Thoracic Surgeons",{"count":59,"type":21},186,"INTERVENTIONAL",[62],"NA","The goal of this interventional is to assess advantages of the ultrasound examination of the lungs in the early postoperative period in cardiac surgical patients after heart surgeries requiring cardiopulmonary bypass. Evaluation of pulmonary complications and outcomes during mid-term follow-up, as well as comparison of ultrasound examination and traditional roentgenologic methods (X-ray examination and CT of the chest) will be performed. The main question\\[s\\] it aims to answer are:\n\n* Is ultrasound examination of the lungs a more specific and sensitive method in identification of early postoperative pulmonary complications after on-pump cardiac surgical procedures, in comparison with traditional X-ray methods.\n* Does early identification of interstitial pulmonary edema (based on number of visualised B-lines in the early postoperative period), influences mid-term outcomes in this cohort of patients Participants will undergo ultrasound examination of the lungs on postoperative day 1, 3, 5 and 7 after heart surgery. Based on ultrasound findings and degree of interstitial pulmonary edema, medical (diuretics, anti-inflammatory, e.t.c) therapy will be modified.\n\nResearchers will compare this group of patients with control group, in which ultrasound examination will be performed in the same time frames, but no changes in medical management based on ultrasound findings will be made to see if timely administered medical therapy, based on ultrasound findings, can significantly improve symptoms, hospital lengths of stay and outcomes of this patients.",[65,66,67,68,69,70,26,71],"Ischemic Heart Disease","Aortic Stenosis, Severe","Aortic Insufficiency","Mitral Stenosis","Mitral Insufficiency","Mitral Stenosis With Insufficiency","Ascending Aortic Aneurysm",[73,74,75,76,77,78],"Ultrasound examination of the lungs","B-lines","Coronary artery bypass grafting","Heart valve surgery","Cardiopulmonary bypass","On-pump cardiac surgery","RECRUITING","2024-12-04",{"date":82,"type":43},"2024-12-09",{"date":84,"type":43},"2024-05-15",{"date":86,"type":21},"2026-01-01",{"name":88,"class":89},"Saint Petersburg State University, Russia","OTHER",1,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":98,"targetDuration":100,"studyType":23,"phases":4,"briefSummary":101,"conditions":102,"keywords":108,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100448084","retrospective-prospective-multicentric-clinical-follow-up-of-patients-after-being-treated-with-tricvalve-100448084","NCT05114850","Retrospective Prospective Multicentric Clinical Follow up of Patients After Being Treated With TricValve®","TRICUS REGISTRY - Retrospective Prospective Multicentric Clinical Follow up of Patients With Severe Tricuspid Regurgitation After Being Treated With the TricValve® Transcatheter Bicaval Valves System.","Inclusion Criteria:\n\n* Successful treatment with TricValve Transcatheter Bicaval Valves System\n* Patient\u002Fpatient's authorized legal guardian gives his consent to participate in the study and signed the corresponding inform consent\n\nExclusion Criteria:\n\n* no exclusion criterion",{"count":99,"type":21},450,"5 Years","Retrospective prospective Multicentric clinical follow up of patients with severe tricuspid regurgitation after being treated with the TricValve® Transcatheter Bicaval Valves System.",[103,104,26,105,106,107],"Tricuspid Regurgitation","Tricuspid Valve Insufficiency","Heart Failure","Heart Diseases","Heart Valve Diseases",[109],"Cardiovascular disease","2024-04-02",{"date":112,"type":43},"2024-04-03",{"date":114,"type":43},"2022-04-20",{"date":116,"type":21},"2028-12",{"name":118,"class":50},"P+F Products + Features GmbH",28]